The Supreme Cannabis Competitors

The Supreme Cannabis (OTCMKTS:SPRWF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares The Supreme Cannabis and Abacus Health Products' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for The Supreme Cannabis and Abacus Health Products, as provided by MarketBeat.

The Supreme Cannabis presently has a consensus target price of $0.3750, indicating a potential upside of 22.95%. Given The Supreme Cannabis' higher probable upside, analysts plainly believe The Supreme Cannabis is more favorable than Abacus Health Products.

Profitability

This table compares The Supreme Cannabis and Abacus Health Products' net margins, return on equity and return on assets.

Summary

The Supreme Cannabis beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

The Supreme Cannabis (OTCMKTS:SPRWF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares The Supreme Cannabis and Acreage's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for The Supreme Cannabis and Acreage, as provided by MarketBeat.

The Supreme Cannabis presently has a consensus target price of $0.3750, indicating a potential upside of 22.95%. Acreage has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Acreage's stronger consensus rating and higher probable upside, analysts plainly believe Acreage is more favorable than The Supreme Cannabis.

Profitability

This table compares The Supreme Cannabis and Acreage's net margins, return on equity and return on assets.

Summary

Acreage beats The Supreme Cannabis on 3 of the 3 factors compared between the two stocks.

The Supreme Cannabis (OTCMKTS:SPRWF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares The Supreme Cannabis and Applied Biosciences' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for The Supreme Cannabis and Applied Biosciences, as provided by MarketBeat.

The Supreme Cannabis presently has a consensus target price of $0.3750, indicating a potential upside of 22.95%. Given The Supreme Cannabis' higher probable upside, analysts plainly believe The Supreme Cannabis is more favorable than Applied Biosciences.

Profitability

This table compares The Supreme Cannabis and Applied Biosciences' net margins, return on equity and return on assets.

Summary

The Supreme Cannabis beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

The Supreme Cannabis (OTCMKTS:SPRWF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares The Supreme Cannabis and Ayr Strategies' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for The Supreme Cannabis and Ayr Strategies, as provided by MarketBeat.

The Supreme Cannabis presently has a consensus target price of $0.3750, indicating a potential upside of 22.95%. Ayr Strategies has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' stronger consensus rating and higher probable upside, analysts plainly believe Ayr Strategies is more favorable than The Supreme Cannabis.

Profitability

This table compares The Supreme Cannabis and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats The Supreme Cannabis on 3 of the 3 factors compared between the two stocks.

The Supreme Cannabis (OTCMKTS:SPRWF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares The Supreme Cannabis and Can B's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for The Supreme Cannabis and Can B, as provided by MarketBeat.

The Supreme Cannabis presently has a consensus target price of $0.3750, indicating a potential upside of 22.95%. Given The Supreme Cannabis' higher probable upside, analysts plainly believe The Supreme Cannabis is more favorable than Can B.

Profitability

This table compares The Supreme Cannabis and Can B's net margins, return on equity and return on assets.

Summary

The Supreme Cannabis beats Can B on 2 of the 2 factors compared between the two stocks.

The Supreme Cannabis (OTCMKTS:SPRWF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares The Supreme Cannabis and Cansortium's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for The Supreme Cannabis and Cansortium, as provided by MarketBeat.

The Supreme Cannabis presently has a consensus target price of $0.3750, indicating a potential upside of 22.95%. Cansortium has a consensus target price of $1.20, indicating a potential upside of 35.90%. Given Cansortium's stronger consensus rating and higher probable upside, analysts plainly believe Cansortium is more favorable than The Supreme Cannabis.

Profitability

This table compares The Supreme Cannabis and Cansortium's net margins, return on equity and return on assets.

Summary

Cansortium beats The Supreme Cannabis on 2 of the 2 factors compared between the two stocks.